Sanofi named a new chief scientific officer this week, part of a series of moves that the drug company has argued will establish it as being more focused on research and development than in the past.
In an internal memo obtained by STAT, Sanofi said Monday that it has named Mike Quigley, formerly the CEO of startups Dualitas Therapeutics and Therini Bio and senior vice president of research biology at Gilead, as its chief scientific officer and global head of research.
“In his new role, Mike’s mission will be to maximize our probability of success through optimal collaborations across our organization and beyond, bringing best in class innovation as well as developing and sourcing new industry leading talent with a commitment to diversity,” wrote Houman Ashrafian, the former venture capitalist who is Sanofi’s head of research and development. Quigley will report to Ashrafian and begin work on Sept. 30.
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.
Already have an account? Log in
